Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Yuri Takada"'
Autor:
Yuri Takada, Hiroaki Itoh, Atmika Paudel, Suresh Panthee, Hiroshi Hamamoto, Kazuhisa Sekimizu, Masayuki Inoue
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-10 (2020)
The strong hemolytic activity and mammalian cytotoxicity of gramicidin A, a peptide antibiotic, has hindered its non-topical clinical application. Here, the authors report a high-throughput strategy for the discovery of gramicidin A analogues with al
Externí odkaz:
https://doaj.org/article/d70f64d57774438f93c1663567f9fba6
Autor:
Harushi Ueno, Yuri Takada, Yoshito Imamura, Shoji Okado, Yuji Nomata, Hiroki Watanabe, Keita Nakanishi, Yuka Kadomatsu, Taketo Kato, Shota Nakamura, Tetsuya Mizuno, Toyofumi Fengshi Chen-Yoshikawa
Publikováno v:
Nagoya Journal of Medical Science; Aug2024, Vol. 86 Issue 3, p464-471, 8p
Autor:
Jiranan Chotitumnavee, Yasunobu Yamashita, Yukari Takahashi, Yuri Takada, Tetsuya Iida, Makoto Oba, Yukihiro Itoh, Takayoshi Suzuki
Publikováno v:
Chemical Communications. 58:4635-4638
We developed a first-in-class proteolysis targeting chimera (PROTAC) for selective degradation of histone deacetylase 8 (HDAC8). The PROTAC induced degradation of HDAC8 without affecting the levels of other HDACs in cellular assays, and inhibited the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cffcc6c0229a2e996a3337b238f808be
https://doi.org/10.1039/d2cc00272h
https://doi.org/10.1039/d2cc00272h
Publikováno v:
JOURNAL OF CHEMICAL ENGINEERING OF JAPAN. 54:103-109
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c53b32a0660f406e1223d8f3e5400104
https://doi.org/10.1252/jcej.20we229
https://doi.org/10.1252/jcej.20we229
Autor:
Friederike M. Dannheim, Nicola Ashman, Hikaru Seki, David R. Spring, Jason S. Carroll, Xiaoxu Ou, Jonathan D Bargh, Andrew J. Counsell, Stephen J. Walsh, Jeremy S. Parker, Albert Isidro-Llobet, Abigail R. Hanby, Yuri Takada, Elaine Fowler
Publikováno v:
Chemical Society Reviews. 50:1305-1353
Antibody-drug conjugates (ADCs) harness the highly specific targeting capabilities of an antibody to deliver a cytotoxic payload to specific cell types. They have garnered widespread interest in drug discovery, particularly in oncology, as discrimina
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2baa0a0dfb660a28b4bd98bef38e89eb
https://doi.org/10.1039/d0cs00310g
https://doi.org/10.1039/d0cs00310g
Autor:
Yosuke Ota, Yukihiro Itoh, Takashi Kurohara, Ritesh Singh, Elghareeb E. Elboray, Chenliang Hu, Farzad Zamani, Anirban Mukherjee, Yuri Takada, Yasunobu Yamashita, Mie Morita, Mano Horinaka, Yoshihiro Sowa, Mitsuharu Masuda, Toshiyuki Sakai, Takayoshi Suzuki
Publikováno v:
ACS medicinal chemistry letters. 13(10)
Anticancer drug delivery by small molecules offers a number of advantages over conventional macromolecular drug delivery systems. We previously developed phenylcyclopropylamine (PCPA)-drug conjugates (PDCs) as small-molecule-based drug delivery vehic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::532973eca856d52a01da6f15b203605f
https://pubmed.ncbi.nlm.nih.gov/36262394
https://pubmed.ncbi.nlm.nih.gov/36262394
Publikováno v:
Journal for the Integrated Study of Dietary Habits. 31:139-150
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::acd680e9261d99e2aa78a9e0d4d3edee
https://doi.org/10.2740/jisdh.31.3_139
https://doi.org/10.2740/jisdh.31.3_139
Autor:
Yuri Takada, Yuki Kitao, Yoshie Fujiwara, Chika Yamamoto, Mitsuhiro Terao, Dan Ohtan Wang, Elghareeb E. Elboray, Yasunobu Yamashita, Yukihiro Itoh, Paolo Mellini, Rohini Roy, Yukari Takahashi, Makoto Oba, Masayuki Kotoku, Takao Yamaguchi, Satoshi Obika, Ritesh Singh, Muthuraj Prakash, Takayoshi Suzuki
Publikováno v:
Journal of medicinal chemistry. 64(21)
Fat mass obesity-associated protein (FTO) is a DNA/RNA demethylase involved in the epigenetic regulation of various genes and is considered a therapeutic target for obesity, cancer, and neurological disorders. Here, we aimed to design novel FTO-selec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cda13918510b1de8b8f693d2d156f972
https://pubmed.ncbi.nlm.nih.gov/34727689
https://pubmed.ncbi.nlm.nih.gov/34727689
Autor:
Satoshi Ueda, Hirokazu Takeshima, Yasunobu Yamashita, Takayoshi Suzuki, Yuri Takada, Keita Tanaka, Shengwang Yu, Yukihiro Itoh, Takashi Kurohara, Koji Hase, Daisuke Takahashi
Publikováno v:
Chembiochem : a European journal of chemical biology. 22(22)
Pharmacological inhibition of histone deacetylase 6 (HDAC6) is an effective therapeutic strategy for cancer and immunological diseases. Most of the previously reported HDAC6 inhibitors have a hydroxamate group as a zinc binding group (ZBG), which coo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf1b0b80ba9dcf129c32ffe3c35a97c8
https://pubmed.ncbi.nlm.nih.gov/34224197
https://pubmed.ncbi.nlm.nih.gov/34224197
Publikováno v:
Current Opinion in Chemical Biology. 67:102130
For many years, drug discovery studies in the field of epigenetics have focused mainly on specific enzymes such as histone deacetylases (HDACs). However, recently there has been increasing interest in small molecules targeting the multiprotein enzyme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71e2ff163bbf49db37ea6d75c15be6c0
https://doi.org/10.1016/j.cbpa.2022.102130
https://doi.org/10.1016/j.cbpa.2022.102130